“Potent Novel GLP-1 Analogue from Bullfrog Shows Superior Efficacy over Semaglutide in Food Intake, Glycemic Control, and Body Weight: Implications for Antiobesity and Antidiabetic Therapies”

https://pubmed.ncbi.nlm.nih.gov/38117235

This study discovered a potent novel GLP-1 analogue from a bullfrog, 2f, which showed superior effects on food intake, glycemic control, and body weight compared to semaglutide, and can be useful for designing GLP-1-based multiagonists for potential antiobesity and antidiabetic therapies.